Exsilio Therapeutics, a Boston-based biotech startup, has secured $82 million in funding and hopes to target genetic conditions with a new approach to gene therapy.
Alnylam Pharmaceuticals, which specializes in developing RNA interference (RNAi) therapeutics to treat genetic diseases, has announced promising clinical trial results for their drug Amvuttra® (vutrisiran)
In the early days of the human immunodeficiency virus (HIV) epidemic, there was little hope. HIV infection, when untreated, damages the immune system, making people
In a pioneering first-in-human clinical trial, an mRNA cancer vaccine developed at the University of Florida (UF) has shown promise in treating patients with primary
RNA editing is emerging as a promising and potentially safer alternative to therapies that modify an individual’s DNA. In December 2023, patients were treated in
In November 2023, the U.S. Food and Drug Administration (FDA) announced an investigation into chimeric antigen receptor (CAR) T-cell therapies, questioning if these promising cancer
Leveraging rapid developments in gene therapy, researchers are designing new ways to target ultra-rare genetic diseases with treatments tailored to a patient’s specific genetic makeup.
Lurking among the vast genetic holdings of the UK Biobank data, researchers uncovered a potential gem — a gene variant linked to cardiometabolic health. Conditions
A groundbreaking gene editing therapy for sickle cell disease from CRISPR Therapeutics and Vertex Pharmaceuticals has received approval from the U.S. Food and Drug Administration.
Although mosquitoes measure less than an inch and weigh a mere 2.5 milligrams, the disease burdens they carry make them the “deadliest animal on Earth,”
RNA-based vaccines have achieved superstar status and Nobel Prize recognition. Now, several biotechnology firms are considering circular RNAs (circRNAs) as a platform for therapeutic development,
In Scotland, the European wildcat, which is about 20% bigger than domestic cats, with denser fur and a thick, blunt tail, is a symbol of
Exsilio Therapeutics, a Boston-based biotech startup, has secured $82 million in funding and hopes to target genetic conditions with a new approach to gene therapy.
Alnylam Pharmaceuticals, which specializes in developing RNA interference (RNAi) therapeutics to treat genetic diseases, has announced promising clinical trial results for their drug Amvuttra® (vutrisiran)
In the early days of the human immunodeficiency virus (HIV) epidemic, there was little hope. HIV infection, when untreated, damages the immune system, making people
In a pioneering first-in-human clinical trial, an mRNA cancer vaccine developed at the University of Florida (UF) has shown promise in treating patients with primary
RNA editing is emerging as a promising and potentially safer alternative to therapies that modify an individual’s DNA. In December 2023, patients were treated in
In November 2023, the U.S. Food and Drug Administration (FDA) announced an investigation into chimeric antigen receptor (CAR) T-cell therapies, questioning if these promising cancer
Leveraging rapid developments in gene therapy, researchers are designing new ways to target ultra-rare genetic diseases with treatments tailored to a patient’s specific genetic makeup.
Lurking among the vast genetic holdings of the UK Biobank data, researchers uncovered a potential gem — a gene variant linked to cardiometabolic health. Conditions
A groundbreaking gene editing therapy for sickle cell disease from CRISPR Therapeutics and Vertex Pharmaceuticals has received approval from the U.S. Food and Drug Administration.
Although mosquitoes measure less than an inch and weigh a mere 2.5 milligrams, the disease burdens they carry make them the “deadliest animal on Earth,”
RNA-based vaccines have achieved superstar status and Nobel Prize recognition. Now, several biotechnology firms are considering circular RNAs (circRNAs) as a platform for therapeutic development,
In Scotland, the European wildcat, which is about 20% bigger than domestic cats, with denser fur and a thick, blunt tail, is a symbol of
Delaware Technology Park,
3 Innovation Way,
Newark, DE 19711
"*" indicates required fields
Emails are serviced by Constant Contact. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.
